I don’t believe I’m being cynical, I think I’m being realistic.
Recall that the formula for insulin was given for free to the university of toronto and now most people in the USA cannot afford insulin even though the cost of creation has not changed since the 1950’s.
It was only extremely recently that 35 dollar insulin became available in the USA and that’s still obscenely overpriced.
I’m curious what cost figure they’re using here because the cost seems odd for Canada. I used to work at a pharmacy and insulin is fully covered by public drug plans (there absolutely needs to be a federally public drug plan), I’m thinking of plans like Trillium in Ontario where you pay a deductible based on yearly income. Employer private insurance to my knowledge would cover it to $0, but possibly not the dispensing fee, which is VERY close to the amount listed here. If they are talking just raw cost per vial with no coverage then that’s possibly accurate, it’s just very rare to actually see that at the register at a pharmacy.
In general I like comparing the US and Canada healthcare regimes because we are pretty much linked to their economy, however seeing where our healthcare over/under performs vs the US you can really link to the differences in the way healthcare is implemented. Broadly speaking we have comparable outcomes, with US and Canada having areas of specialty, however the cost spent by the US on healthcare per capita is insanely higher. People will pad this by claiming that money is because of healthcare research in the US which “the world benefits from at our cost” but the figures aren’t often added together in that way. It really is the delivery of healthcare in the US where there are insane costs compared to every other G20 country with detailed healthcare data.
The insane addition in the USA is due to so many middle men working to up the cost basis to increase their bottom line, essentially the insurance companies are running a racket.
Here is the associated research report that the link I provided used for their data aggregation and comparisons:
Specifically for your question about cost basis it seems they tallied the total price for the insulin based on its chemical costs (for each type of insulin) and then cross referenced that with the price placed down on both prescription drugs and over the counter drugs listed in the IQVIA MIDAS database:
“In our analysis, we used prescription-drug market data from IQVIA’s MIDAS database.2 The
data we examined cover the year 2018 and span 33 Organisation for Economic Co-operation and
Development (OECD) countries, including the United States.3 We did not restrict our analysis to
prescription drugs, as certain insulins are available over the counter in some countries (including
the United States).” - RAND RRA788 PDF Page 2, Paragraph 2; Mulcahy, Schawm & Edenfield “Comparing insulin prices in the United States to Other Countries” 2020.
Once they had a general understanding and baseline for what the products should cost they then indexed and compared prices globally using volume weighted pricing, they do note specifically that the manufacturer prices they used from MIDAS does not reflect rebates or discounts that would exist at point of sale (RAND RRA788 Pg 3 Para 2).
These are the references the research paper provided:
Cefalu, William T., Daniel E. Dawes, Gina Gavlak, Dana Goldman, William H. Herman, Karen
Van Nuys, Alvin C. Powers, Simeon I. Taylor, and Alan L. Yatvin, on behalf of the Insulin
Access and Affordability Working Group, “Insulin Access and Affordability Working
Group: Conclusions and Recommendations,” Diabetes Care, Vol. 41, No. 8, August 2018,
pp. 1299–1311.
Fuglesten Biniek, Jean, and William Johnson, “Spending on Individuals with Type 1 Diabetes
and the Role of Rapidly Increasing Insulin Prices,” Health Care Cost Institute, January 21,
2019. As of September 1, 2020:
https://healthcostinstitute.org/diabetes-and-insulin/spending-on-individuals-with-type-1-
diabetes-and-the-role-of-rapidly-increasing-insulin-prices
Can’t wait for it to be specifically priced for only the 1% to be able to afford. Just like all the other cancer drugs that work.
It’s for rich folk. Not for us poors. Elysium.
Why be that cynical about it? All technology is only for the rich when it’s first introduced.
I don’t believe I’m being cynical, I think I’m being realistic.
Recall that the formula for insulin was given for free to the university of toronto and now most people in the USA cannot afford insulin even though the cost of creation has not changed since the 1950’s.
It was only extremely recently that 35 dollar insulin became available in the USA and that’s still obscenely overpriced.
Reference: https://worldpopulationreview.com/country-rankings/cost-of-insulin-by-country
I’m curious what cost figure they’re using here because the cost seems odd for Canada. I used to work at a pharmacy and insulin is fully covered by public drug plans (there absolutely needs to be a federally public drug plan), I’m thinking of plans like Trillium in Ontario where you pay a deductible based on yearly income. Employer private insurance to my knowledge would cover it to $0, but possibly not the dispensing fee, which is VERY close to the amount listed here. If they are talking just raw cost per vial with no coverage then that’s possibly accurate, it’s just very rare to actually see that at the register at a pharmacy.
In general I like comparing the US and Canada healthcare regimes because we are pretty much linked to their economy, however seeing where our healthcare over/under performs vs the US you can really link to the differences in the way healthcare is implemented. Broadly speaking we have comparable outcomes, with US and Canada having areas of specialty, however the cost spent by the US on healthcare per capita is insanely higher. People will pad this by claiming that money is because of healthcare research in the US which “the world benefits from at our cost” but the figures aren’t often added together in that way. It really is the delivery of healthcare in the US where there are insane costs compared to every other G20 country with detailed healthcare data.
The insane addition in the USA is due to so many middle men working to up the cost basis to increase their bottom line, essentially the insurance companies are running a racket.
Here is the associated research report that the link I provided used for their data aggregation and comparisons:
https://www.rand.org/content/dam/rand/pubs/research_reports/RRA700/RRA788-1/RAND_RRA788-1.pdf
These are the associated surveys:
https://www.t1international.com/access-survey16/
https://www.t1international.com/access-survey18/
https://www.t1international.com/access-survey/
Specifically for your question about cost basis it seems they tallied the total price for the insulin based on its chemical costs (for each type of insulin) and then cross referenced that with the price placed down on both prescription drugs and over the counter drugs listed in the IQVIA MIDAS database:
“In our analysis, we used prescription-drug market data from IQVIA’s MIDAS database.2 The data we examined cover the year 2018 and span 33 Organisation for Economic Co-operation and Development (OECD) countries, including the United States.3 We did not restrict our analysis to prescription drugs, as certain insulins are available over the counter in some countries (including the United States).” - RAND RRA788 PDF Page 2, Paragraph 2; Mulcahy, Schawm & Edenfield “Comparing insulin prices in the United States to Other Countries” 2020.
(IQVIA MIDAS: https://www.iqvia.com/solutions/commercialization/brand-strategy-and-management/market-measurement/midas)
Once they had a general understanding and baseline for what the products should cost they then indexed and compared prices globally using volume weighted pricing, they do note specifically that the manufacturer prices they used from MIDAS does not reflect rebates or discounts that would exist at point of sale (RAND RRA788 Pg 3 Para 2).
These are the references the research paper provided:
Cefalu, William T., Daniel E. Dawes, Gina Gavlak, Dana Goldman, William H. Herman, Karen Van Nuys, Alvin C. Powers, Simeon I. Taylor, and Alan L. Yatvin, on behalf of the Insulin Access and Affordability Working Group, “Insulin Access and Affordability Working Group: Conclusions and Recommendations,” Diabetes Care, Vol. 41, No. 8, August 2018, pp. 1299–1311.
Fuglesten Biniek, Jean, and William Johnson, “Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices,” Health Care Cost Institute, January 21, 2019. As of September 1, 2020: https://healthcostinstitute.org/diabetes-and-insulin/spending-on-individuals-with-type-1- diabetes-and-the-role-of-rapidly-increasing-insulin-prices
IQVIA, “MIDAS,” webpage, undated. As of September 1, 2020: https://www.iqvia.com/solutions/commercialization/brand-strategy-and-management/market- measurement/midas
IQVIA Institute for Human Data Science, Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023, Durham, N.C., May 9, 2019.
Roehrig, Charles, The Impact of Prescription Drug Rebates on Health Plans and Consumers, Ann Arbor, Mich.: Altarum Institute, April 2018.
Tribble, Sarah Jane, “You Can Buy Insulin Without a Prescription, but Should You?” Kaiser Health News, December 14, 2015. As of August 20, 2020: https://khn.org/news/you-can-buy-insulin-without-a-prescription-but-should-you/